Shares in Japanese biopharma venture AnGes Inc. continued to surge Tuesday, as its much-hyped coronavirus vaccine candidate moved closer to starting human trials.
Shares jumped as much as 19 percent in Tokyo trading, taking its gaining streak to a fourth day, after the Nikkei newspaper reported late Monday that it would begin clinical trials for its DNA vaccine in July, earlier than previously planned. The stock closed at the highest level since 2008.
That report followed the announcement by AnGes that animal trials of the vaccine had confirmed an increase in antibodies in tests it had been conducting with Osaka University since March.